Review
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Apr 27, 2014; 6(4): 169-177
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.169
Lipid lowering effects of iodothyronines: In vivo and in vitro studies on rat liver
Laura Vergani
Laura Vergani, Dipartimento di Scienze della Terra, dell’Ambiente e della Vita, Università degli Studi di Genova, 16132 Genova, Italy
Author contributions: Vergani L solely contributed to this paper.
Correspondence to: Laura Vergani, PhD, Assistant Professor, Dipartimento di Scienze della Terra, dell’Ambiente e della Vita, Università degli Studi di Genova, DISTAV, Corso Europa 26, 16132 Genova, Italy. laura.vergani@unige.it
Telephone: +39-10-3538403 Fax: +39-10-3538403
Received: October 28, 2013
Revised: December 22, 2013
Accepted: January 17, 2014
Published online: April 27, 2014
Processing time: 203 Days and 19.4 Hours
Core Tip

Core tip: This review summarizes the recent insights about the mechanisms underlying the lipid lowering action of iodothyronines. In the last decades, extensive studies investigated the possible use of iodothyronines in the treatment of obesity and dysmetabolic syndromes. Since the pharmacological use of thyroid hormones has found severe limitations because of their thyrotoxic effects, the identification of iodothyronines retaining anti-obesity and hypolipemic efficacies, while being devoid of thyrotoxicity, gained great interest. The review discusses the recent studies employing both in vivo and in vitro models of hepatosteatosis, with particular attention to the in vitro studies demonstrating the direct anti-steatotic effect of iodothyronines.